What are the benefits and risks of Depo‑Provera (medroxyprogesterone acetate) as a contraceptive?

Depo-Provera Risks and Benefits

Depo-Provera (DMPA) is a highly effective contraceptive with proven benefits including high efficacy and convenience, but carries significant risks including bone mineral density loss (particularly concerning in adolescents), delayed return to fertility, irregular bleeding, and emerging evidence of increased meningioma risk with prolonged use, especially when started after age 31. 1, 2

Primary Benefits

Contraceptive Efficacy

• Highly effective contraception with proven long-term safety over 40 years of worldwide use 3
• Can be self-administered (subcutaneous formulation) to improve access and reproductive autonomy 4
• Injections required every 3 months (13 weeks), with up to 2-week grace period (15 weeks total) without requiring backup contraception 4

Non-Contraceptive Benefits

• Decreased risk of certain cancers (limited evidence) 5
• Reduced risk of tubal infertility (limited evidence) 5
• No increased risk of cardiovascular events, breast cancer (in most populations), or gynecologic malignancy based on long-term data 3, 6

Major Risks and Adverse Effects

Bone Health (Critical Concern)

Bone mineral density (BMD) loss is the most significant concern, particularly in adolescents and young adults during critical bone accretion periods 1:

• Loss of BMD occurs with use, though it's unknown if this reduces peak bone mass or increases osteoporotic fracture risk later in life
• Adolescents are at highest risk due to timing during peak bone development
• Interpretation of BMD results must account for patient age and skeletal maturity
• No increased risk of postmenopausal fracture has been documented in long-term studies 6

Reproductive Effects

• Delayed return to fertility after discontinuation—women may experience significant delays in return to ovulation and conception 1
• This is expected and reversible but should be discussed upfront with patients planning future pregnancy

Menstrual Changes

Irregular bleeding and amenorrhea are extremely common 7, 5:

• Spotting, light bleeding, heavy bleeding, or prolonged bleeding frequently occur
• Amenorrhea develops in many users
• These are the most common reasons for discontinuation
• Management options include NSAIDs for 5-7 days for bleeding irregularities 7

Weight and Metabolic Effects

• Weight gain and increased body fat mass are associated with DMPA use (moderate to high risk of bias in studies) 5
• Effects on lipid metabolism are inconsistent—both increases and decreases in cholesterol, triglycerides, LDL, and HDL have been observed 1

Neurological Risk (Emerging Evidence)

Recent high-quality 2025 data shows increased meningioma risk with depot DMPA 2:

• Relative risk of 2.43 (95% CI 1.77-3.33) compared to controls
• Risk is confined to exposures >4 years OR starting at age >31 years
• Number needed to harm: 1,152 patients (low absolute risk)
• This risk is specific to cerebral meningiomas and strengthens with longer duration of use 8
• Oral MPA shows lower risk (RR 1.18) 2

Other Adverse Effects

• Mood and libido changes: inconsistent evidence exists 5
• Injection site reactions including abscess and infections (strict aseptic technique required) 1
• Unexpected signals from pharmacovigilance data include: unintended pregnancy (contraceptive failure), bone pain, gait disturbance, dental caries, blood pressure changes, and osteonecrosis 9

Breast Cancer Risk

Current and recent users, especially women <35 years, may have slightly increased breast cancer risk 10:

• Most studies show no overall elevated risk
• Possible increased incidence in current/recent users under age 35
• Long-term use did not increase risk
• Overall evidence suggests little to no increased overall breast cancer risk 6, 10

Special Populations

Adolescents

• Same safety and effectiveness as adults except for BMD concerns 1
• Not indicated before menarche
• Bone health concerns are paramount in this age group during critical bone accretion

Breastfeeding

• Initiate during or after 6th postpartum week in exclusively breastfeeding mothers 1
• Effects on milk production/lactation initiation unclear if given before 6 weeks
• Detectable in breast milk but no adverse effects in breastfed infants documented
• Milk composition, quality, and amount not adversely affected

Drug Interactions

Enzyme inducers (CYP3A4) may decrease effectiveness 1:

• Barbiturates, carbamazepine, phenytoin, rifampin, St. John's wort, topiramate
• Counsel patients to use additional contraception or different method
• HIV protease inhibitors and NNRTIs can cause significant changes in progestin levels
• Antibiotic effects are inconsistent and not clinically significant

Clinical Decision Algorithm

For patients considering DMPA:

1. Age <18 years: Counsel extensively about BMD loss during critical bone development; consider alternative methods unless patient strongly prefers DMPA
2. Age >31 years planning long-term use (>4 years): Discuss emerging meningioma risk; consider alternative long-acting methods
3. Breastfeeding: Wait until 6 weeks postpartum
4. Desiring near-term pregnancy: Choose different method due to delayed return to fertility
5. All patients: Counsel about irregular bleeding (most common reason for discontinuation), weight gain, and delayed fertility return

Common Pitfalls to Avoid

• Failing to counsel adolescents about BMD loss and its unknown long-term implications
• Starting DMPA before 6 weeks postpartum in breastfeeding women
• Not discussing delayed return to fertility with women planning pregnancy within 1-2 years
• Inadequate counseling about bleeding irregularities leading to premature discontinuation
• Ignoring emerging meningioma data in women >31 years considering long-term use
• Not using strict aseptic technique for injections